Pulmonary Hypertension in Bronchopulmonary Dysplasia

  • Steven H. AbmanEmail author
Part of the Respiratory Medicine book series (RM)


Pulmonary vascular disease (PVD) and related pulmonary hypertension (PH) contribute significantly to the pathogenesis, cardiorespiratory morbidities, and poor outcomes in preterm infants with BPD. Past studies have shown that persistent echocardiogram evidence of PH beyond the first few months of life is associated with up to 40 % mortality in infants with BPD. The association of PH with poor survival in BPD has continued into the recent era of the “new BPD,” especially in infants with severe disease who require prolonged support with mechanical ventilation. More recent studies have shown that adverse antenatal or early postnatal stimuli impair pulmonary vascular development and function, leading to disruption of angiogenesis and distal lung airspace growth. Consensus guidelines for the diagnosis, evaluation, and management of PH in infants with established BPD have recently been published by a consensus committee; however, clinical care remains controversial due to the lack of strong evidence-based data. Overall, understanding the pathogenesis and pathobiology of early PVD in BPD continues as an important challenge and may help to improve early and late cardiopulmonary outcomes after preterm birth. Future large-scale studies of interventions for the treatment of PH in established BPD are needed. In addition, strategies that specifically target the preservation of endothelial survival and function may also lead to novel approaches for the prevention of BPD and late PH.


Pulmonary arterial hypertension Prematurity Bronchopulmonary dysplasia Pulmonary vascular disease Lung vascular development Inhaled nitric oxide 


  1. 1.
    Northway WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline membrane disease. Bronchopulonary dysplasia. N Engl J Med. 1967;276:357–68.CrossRefPubMedGoogle Scholar
  2. 2.
    Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Jobe AH. The new BPD: an arrest of lung development. Pediatr Res. 1999;46:641–3.CrossRefPubMedGoogle Scholar
  4. 4.
    Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med. 2007;357(19):1946–55.CrossRefPubMedGoogle Scholar
  5. 5.
    Hussain AN, Siddiqui NH, Stocker JT. Pathology of arrested acinar development in postsurfactant BPD. Hum Pathol. 1998;29:710–7.CrossRefGoogle Scholar
  6. 6.
    McEvoy C, Jain L, Schmidt B, Abman SH, Bancalari E, Aschner J. Bronchopulmonary dysplasia: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc. 2014;Suppl 3:S146–53.CrossRefGoogle Scholar
  7. 7.
    Stoll BJ, Hansen NI, Bell EF, et al. Trends in care practices, morbidity and mortality of extremely preterm neonates. JAMA. 2015;314:1039–51.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Wong PM, Lees AN, Louw J, et al. Emphysema in young adult survivors of moderate-to-severe bronchopulmonary dysplasia. Eur Respir J. 2008;32(2):321–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Hislop AA, Haworth SG. Pulmonary vascular damage and the development of cor pulmonale following hyaline membrane disease. Pediatr Pulmonol. 1990;9:152–161.Google Scholar
  10. 10.
    Bush A, Busst CM, Knight WB, Hislop AA, Haworth SG, Shinebourne EA. Changes in the pulmonary circulation in BPD. Arch Dis Child. 1990;65:739–45.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Fouron JC, Le Guennec JC, Villemant D, et al. Value of echocardiography in assessing the outcome of bronchopulmonary dysplasia of the newborn. Pediatrics. 1980;65(3):529–35.PubMedGoogle Scholar
  12. 12.
    Abman SH. Pulmonary hypertension in chronic lung disease of infancy. Pathogenesis, pathophysiology and treatment. In: Bland RD, Coalson JJ, editors. Chronic lung disease of infancy. New York: Marcel Dekker; 2000. p. 619–68.Google Scholar
  13. 13.
    Mourani PM, Sontag MK, Younoszai A, Miller JI, Kinsella JP, Baker CD, Poindexter BB, Ingram DA, Abman SH. Early pulmonary vascular disease in preterm infants at risk for BPD. Am J Respir Crit Care Med. 2015;191:87–95.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Mirza H, Ziegler J, Ford S, Padbury J, Tucker R, Laptook A. Pulmonary hypertension in preterm infants: prevalence and association with bronchopulmonary dysplasia. J Pediatr. 2014;165(5):909–14.e1.CrossRefPubMedGoogle Scholar
  15. 15.
    Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007;120(6):1260–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Abman SH, Hansmann G, Archer S, et al. American Heart Association and American Thoracic Society Joint Guidelines for Pediatric Pulmonary Hypertension. Circulation. 2015;132:2037–99.CrossRefPubMedGoogle Scholar
  17. 17.
    Stenmark KR, Abman SH. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol. 2005;67:623–61.CrossRefPubMedGoogle Scholar
  18. 18.
    Thebaud B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med. 2007;175(10):978–85.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Bhatt AJ, Pryhuber GS, Huyck H, et al. Disrupted pulmonary vasculature and decreased VEGF, flt-1, and Tie 2 in human infants dying with BPD. Am J Respir Crit Care Med. 2000;164:1971–80.CrossRefGoogle Scholar
  20. 20.
    Lassus P, Turanlahti M, Heikkila P, et al. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1981–7.CrossRefPubMedGoogle Scholar
  21. 21.
    De Paepe ME, Mao Q, Powell J, et al. Growth of pulmonary microvasculature in ventilated preterm infants. Am J Respir Crit Care Med. 2006;173(2):204–11.CrossRefPubMedGoogle Scholar
  22. 22.
    Mourani PM, Abman SH. Pulmonary vascular disease in BPD: physiology, diagnosis and treatment. In: Abman SH, editor. Bronchopulmonary dysplasia. New York: Informa; 2010. p. 347–63.Google Scholar
  23. 23.
    Jakkula M, Le Cras TD, Gebb S, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol. 2000;279:L600–7.PubMedGoogle Scholar
  24. 24.
    Abman SH. BPD: a vascular hypothesis. Am J Respir Crit Care Med. 2001;164:1755–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Abman SH. Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. Adv Exp Med Biol. 2010;661:323–35.CrossRefPubMedGoogle Scholar
  26. 26.
    Balinotti JE, Chakr VC, Tiller C, et al. Growth of lung parenchyma in infants and toddlers with chronic lung disease of infancy. Am J Respir Crit Care Med. 2010;181(10):1093–7.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hansen AR, Barnes CM, Folkman J, McElrath TF. Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr. 2010;156(4):532–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Foidart JM, Schaaps JP, Chantraine F, Munaut C, Lorquet S. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia – a step forward but not the definitive answer. J Reprod Immunol. 2009;82(2):106–11.CrossRefPubMedGoogle Scholar
  29. 29.
    Tang JR, Karumanchi SA, Seedorf G, Markham N, Abman SH. Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2012;302(1):L36–46.CrossRefPubMedGoogle Scholar
  30. 30.
    Li F, Hagaman JR, Kim HS, et al. eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype. J Am Soc Nephrol. 2012;23(4):652–60.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Rozance PJ, Seedorf GJ, Brown A, et al. Intrauterine growth restriction decreases pulmonary alveolar and vessel growth and causes pulmonary artery endothelial cell dysfunction in vitro in fetal sheep. Am J Physiol Lung Cell Mol Physiol. 2011;301(6):L860–71.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Check J, Gotteiner N, Liu X, et al. Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia. J Perinatol. 2013;33:553–7.Google Scholar
  33. 33.
    Evans NJ, Archer LNJ. Doppler assessment of pulmonary artery pressure during recovery from hyaline membrane disease. Arch Dis Child. 1991;66:802–4.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Subhedar NV, Shaw NJ. Changes in pulmonary arterial pressure in preterm infants with chronic lung disease. Arch Dis Child. 2000;82:F243–7.CrossRefGoogle Scholar
  35. 35.
    Czernik C, Rhode S, Metze B, Schmalisch G, Buhrer C. Persistently elevated right ventricular index of myocardial performance in preterm infants with incipient bronchopulmonary dysplasia. PLoS One. 2012;7(6):e38352.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Skinner JR, Boys RJ, Hunter S, Hey EN. Pulmonary and systemic arterial pressure in hyaline membrane disease. Arch Dis Child. 1992;67(4 Spec No):366–73.Google Scholar
  37. 37.
    Abman SH, Wolfe RR, Accurso FJ, Koops BL, Wiggins JW. Pulmonary vascular response to to oxygen in infants with severe BPD. Pediatrics. 1985;75:80–4.PubMedGoogle Scholar
  38. 38.
    Mourani P, Ivy DD, Gao D, Abman SH. Pulmonary vascular effects of inhaled NO and oxygen tension in older children and adolescents with bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2004;170:1006–13.CrossRefPubMedGoogle Scholar
  39. 39.
    Galambos C, Sims-Lucas S, Abman SH. Histologic evidence of intrapulmonary arteriovenous shunt vessels in premature infants with severe bpd. Ann Am Thorac Soc. 2013;10:474–81.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Abman SH, Schaffer MS, Wiggins JW, et al. Pulmonary vascular extraction of circulating norepinephrine in infants with BPD. Pediatr Pulmonol. 1987;3:386–91.CrossRefPubMedGoogle Scholar
  41. 41.
    An HS, Bae EJ, Kim GB, et al. Pulmonary hypertension in preterm infants with BPD. Korean Circ J. 2010;40:131–6.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Slaughter JR, Pakradhi T, Lones DE et al. Echocardiographic detection of pulmonary hypertension in extremely low birth weight infants with BPD requiring prolonged positive pressure ventilation. J Perinatol. 2011;31:1–6.Google Scholar
  43. 43.
    Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol. 1985;6(4):750–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Mourani PM, Sontag MK, Younoszai A, et al. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics. 2008;121(2):317.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Drossner DM, Kim DW, Maher KO, et al. Pulmonary vein stenosis: prematurity and associated conditions. Pediatrics. 2008;122:e656–61.CrossRefPubMedGoogle Scholar
  46. 46.
    Mourani PM, Fagan T, Ivy DD, Rosenberg A, Abman SH. Left ventricular diastolic dysfunction in bronchopulmonary dysplasia. J Pediatr. 2008;152:291–3.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Del Cerro MJ, Sabate-Rotes A, Carton A, et al. Pulmonary hypertension in BPD: clinical findings, cardiovascular abnormalities and outcomes. Pediatr Pulmonol. 2014;49:49–59.CrossRefPubMedGoogle Scholar
  48. 48.
    Banks BA, Seri I, Ischiropoulos H, et al. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics. 1999;103(3):610–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Baquero H, Soliz A, Neira F, et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics. 2006;117(4):1077–83.CrossRefPubMedGoogle Scholar
  50. 50.
    Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation. 2005;111(24):3274–80.CrossRefPubMedGoogle Scholar
  51. 51.
    Mourani PM, Sontag MK, Lui G, et al. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr. 2008;121:317–25.Google Scholar
  52. 52.
    Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(4):697–704.CrossRefPubMedGoogle Scholar
  53. 53.
    Brownlee JR, Beekman RH, Rosenthal A. Acute hemodynamic effects of nifedipine in infants with bronchopulmonary dysplasia and pulmonary hypertension. Pediatr Res. 1988;24(2):186–90.CrossRefPubMedGoogle Scholar
  54. 54.
    Johnson CE, Beekman RH, Kostyshak DA, et al. Pharmacokinetics and pharmacodynamics of nifedipine in children with bronchopulmonary dysplasia and pulmonary hypertension. Pediatr Res. 1991;29(5):500–3.CrossRefPubMedGoogle Scholar
  55. 55.
    Ferdman DJ, Rosenzweig EB, Zuckerman WA, Krishnan U. Subcutaneous treprostinil for pulmonary hypertension in chronic lung disease of infancy. Pediatrics. 2014;134:e274–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Pediatric Heart Lung Center, Sections of Pediatric Pulmonary MedicineUniversity of Colorado School of Medicine and Children’s Hospital ColoradoAuroraUSA
  2. 2.Critical Care MedicineUniversity of Colorado School of Medicine and Children’s Hospital ColoradoAuroraUSA
  3. 3.Department of PediatricsUniversity of Colorado School of Medicine and Children’s Hospital ColoradoAuroraUSA

Personalised recommendations